Personalized medicine in psychiatry

Nordic Journal of Psychiatry

Volumn 71, Issue 1, 2017, Pages 12-19

  Wium Andersen, Ida Kim ^a   Vinberg, Maj ^b   Kessing, Lars Vedel ^b   McIntyre, Roger S ^c  

^a Psychiatric Center Ballerup   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Biomarkers; diagnostic system; genetics; personalized medicine; psychiatry; RDoC; taxonomy

Indexed keywords

BIOLOGY; CLINICAL PRACTICE; GENETICS; HUMAN; PERSONALIZED MEDICINE; PSYCHIATRY; RISK FACTOR; TAXONOMY; PROCEDURES;

HUMANS; PRECISION MEDICINE; PSYCHIATRY;

EID: 85006988034     PISSN: 08039488     EISSN: 15024725     Source Type: Journal    
DOI: 10.1080/08039488.2016.1216163     Document Type: Review

References (108)

1. Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR., The STAR*D Project results:A comprehensive review of findings. Curr Psychiatry Rep 2007;9:449–59.
2. NRC. Toward precision medicine:Building a knowledge network for biomedical research and a new taxonomy of disease. The National Academies Collection:Reports funded by National Institutes of Health. Washington (DC), 2011.
3. Schleidgen S, Klingler C, Bertram T, Rogowski WH, Marckmann G., What is personalized medicine:sharpening a vague term based on a systematic literature review. BMC Med Ethics 2013;14:55.
4. Hasler G, Wolf A., Toward stratified treatments for bipolar disorders. Eur Neuropsychopharmacol 2015;25:283–94.
5. Jones AG, Shields BM, Hyde CJ, Henley WE, Hattersley AT., Identifying good responders to glucose lowering therapy in type 2 diabetes:Implications for stratified medicine. PLoS One 2014;9:e111235.
6. Kapur S, Phillips AG, Insel TR., Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it? Mol Psychiatry 2012;17:1174–9.
7. Tandon R, Gaebel W, Barch DM, Bustillo J, Gur RE, Heckers S, et al. Definition and description of schizophrenia in the DSM-5. Schizophr Res 2013;150:3–10.
8. Newmark CS, Raft D, Toomey T, Hunter W, Mazzaglia J., Diagnosis of schizophrenia:Pathognomonic signs or symptom clusters. Compr Psychiatry 1975;16:155–63.
9. Regier DA, Narrow WE, Clarke DE, Kraemer HC, Kuramoto SJ, Kuhl EA, et al. DSM-5 field trials in the United States and Canada, Part II:Test-retest reliability of selected categorical diagnoses. Am J Psychiatry 2013;170:59–70.
10. Mitchell PB, Goodwin GM, Johnson GF, Hirschfeld RM., Diagnostic guidelines for bipolar depression:A probabilistic approach. Bipolar Disord 2008;10:144–52.
11. Li CT, Bai YM, Huang YL, Chen YS, Chen TJ, Cheng JY, et al. Association between antidepressant resistance in unipolar depression and subsequent bipolar disorder:Cohort study. Br J Psychiatry 2012;200:45–51.
12. Kessing LV, Hellmund G, Andersen PK., Predictors of excellent response to lithium:Results from a nationwide register-based study. Int Clin Psychopharmacol 2011;26:323–8.
13. Kessing LV, Vradi E, Andersen PK., Starting lithium prophylaxis early v. late in bipolar disorder. Br J Psychiatry 2014;205:214–20.
14. Strimbu K, Tavel JA., What are biomarkers? Curr Opin HIV AIDS 2010;5:463–6.
15. Enaw JO, Smith AK., Biomarker development for brain-based disorders:Recent progress in psychiatry. J Neurol Psychol 2013;1:7
16. Vasan RS., Biomarkers of cardiovascular disease:Molecular basis and practical considerations. Circulation 2006;113:2335–62.
17. Kalia M, Costa ESJ., Biomarkers of psychiatric diseases:Current status and future prospects. Metab Clin Exp 2015;64:S11–15.
18. Singh I, Rose N., Biomarkers in psychiatry. Nature 2009;460:202–7.
19. Harris LW, Pietsch S, Cheng TM, Schwarz E, Guest PC, Bahn S., Comparison of peripheral and central schizophrenia biomarker profiles. PLoS One 2012;7:e46368.
20. Jones KA, Thomsen C., The role of the innate immune system in psychiatric disorders. Mol Cell Neurosci 2013;53:52–62.
21. Muller N, Weidinger E, Leitner B, Schwarz MJ., The role of inflammation in schizophrenia. Front Neurosci 2015;9:372.
22. Raison CL, Capuron L, Miller AH., Cytokines sing the blues:Inflammation and the pathogenesis of depression. Trends Immunol 2006;27:24–31.
23. Wysokinski A, Margulska A, Strzelecki D, Kloszewska I., Levels of C-reactive protein (CRP) in patients with schizophrenia, unipolar depression and bipolar disorder. Nord J Psychiatry 2015;69:346–53.
24. Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression:The role of baseline inflammatory biomarkers. JAMA Psychiatry 2013;70:31–41.
25. Sullivan PF, Kendler KS, Neale MC., Schizophrenia as a complex trait:Evidence from a meta-analysis of twin studies. Arch Gen Psychiatry 2003;60:1187–92.
26. Polderman TJ, Benyamin B, de Leeuw CA, Sullivan PF, van Bochoven A, Visscher PM., Meta-analysis of the heritability of human traits based on fifty years of twin studies. Nat Genet 2015;47:702–9.
27. Collins FS. Shattuck lecture-medical and societal consequences of the human genome project. N Engl J Med 1999;341:28–37.
28. Jaffe AE, Deep-Soboslay A, Tao R, Hauptman DT, Kaye WH, Arango V, et al. Genetic neuropathology of obsessive psychiatric syndromes. Transl Psychiatry 2014;4:e432.
29. Sanders AR, Duan J, Levinson DF, Shi J, He D, Hou C, et al. No significant association of 14 candidate genes with schizophrenia in a large European ancestry sample:Implications for psychiatric genetics. Am J Psychiatry 2008;165:497–506.
30. Psychiatric GCCC, Cichon S, Craddock N, Daly M, Faraone SV, Gejman PV, et al. Genomewide association studies:History, rationale, and prospects for psychiatric disorders. Am J Psychiatry 2009;166:540–56.
31. Sullivan PF., The psychiatric GWAS consortium:Big science comes to psychiatry. Neuron 2010;68:182–6.
32. Psychiatric GCBDWG. Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. Nat Genet 2011;43:977–83.
33. Schizophrenia Working Group of the Psychiatric Genomics C. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014;511:421–7.
34. Major Depressive Disorder Working Group of the Psychiatric GC, Ripke S, Wray NR, Lewis CM, Hamilton SP, Weissman MM, et al. A mega-analysis of genome-wide association studies for major depressive disorder. Mol Psychiatry 2013;18:497–511.
35. Fabbri C, Porcelli S, Serretti A., From pharmacogenetics to pharmacogenomics:The way toward the personalization of antidepressant treatment. Can J Psychiatry 2014;59:62–75.
36. Haijma SV, Van Haren N, Cahn W, Koolschijn PC, Hulshoff Pol HE, Kahn RS., Brain volumes in schizophrenia:A meta-analysis in over 18 000 subjects. Schizophr Bull 2013;39:1129–38.
37. Sayo A, Jennings RG, Van Horn JD., Study factors influencing ventricular enlargement in schizophrenia:A 20 year follow-up meta-analysis. Neuroimage 2012;59:154–67.
38. Wright IC, Rabe-Hesketh S, Woodruff PW, David AS, Murray RM, Bullmore ET., Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry 2000;157:16–25.
39. Linden DE, Fallgatter AJ., Neuroimaging in psychiatry:From bench to bedside. Front Hum Neurosci 2009;3:49.
40. McDonald C, Marshall N, Sham PC, Bullmore ET, Schulze K, Chapple B, et al. Regional brain morphometry in patients with schizophrenia or bipolar disorder and their unaffected relatives. Am J Psychiatry 2006;163:478–87.
41. Arnone D, Cavanagh J, Gerber D, Lawrie SM, Ebmeier KP, McIntosh AM., Magnetic resonance imaging studies in bipolar disorder and schizophrenia:Meta-analysis. Br J Psychiatry 2009;195:194–201.
42. McDonald C, Zanelli J, Rabe-Hesketh S, Ellison-Wright I, Sham P, Kalidindi S, et al. Meta-analysis of magnetic resonance imaging brain morphometry studies in bipolar disorder. Biol Psychiatry 2004;56:411–17.
43. Lorenzetti V, Allen NB, Fornito A, Yucel M., Structural brain abnormalities in major depressive disorder:A selective review of recent MRI studies. J Affect Disord 2009;117:1–17.
44. Beyer JL, Krishnan KR., Volumetric brain imaging findings in mood disorders. Bipolar Disord 2002;4:89–104.
45. Karl A, Schaefer M, Malta LS, Dorfel D, Rohleder N, Werner A., A meta-analysis of structural brain abnormalities in PTSD. Neurosci Biobehav Rev 2006;30:1004–31.
46. Scarr E, Millan MJ, Bahn S, Bertolino A, Turck CW, Kapur S, et al. Biomarkers for psychiatry:The journey from fantasy to fact, a report of the 2013 CINP think tank. Int J Neuropsychopharmacol 2015;18:pyv042.
47. Papakostas GI, Shelton RC, Kinrys G, Henry ME, Bakow BR, Lipkin SH, et al. Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder:A pilot and replication study. Mol Psychiatry 2013;18:332–9.
48. Munkholm K, Peijs L, Vinberg M, Kessing LV., A composite peripheral blood gene expression measure as a potential diagnostic biomarker in bipolar disorder. Transl Psychiatry 2015;5:e614.
49. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 2012;69:98–106.
50. National Institute for Health and Clinical Excellence M. Dementia:Supporting people with dementia and their carers in health and social care. 2006.
51. Malhotra AK, Zhang JP, Lencz T., Pharmacogenetics in psychiatry:Translating research into clinical practice. Mol Psychiatry 2012;17:760–9.
52. Laje G, McMahon FJ., Genome-wide association studies of antidepressant outcome:A brief review. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:1553–7.
53. Razafsha M, Khaku A, Azari H, Alawieh A, Behforuzi H, Fadlallah B, et al. Biomarker identification in psychiatric disorders:From neuroscience to clinical practice. J Psychiatr Pract 2015;21:37–48.
54. Dunlop BW, Mayberg HS., Neuroimaging-based biomarkers for treatment selection in major depressive disorder. Dialogues Clin Neurosci 2014;16:479–90.
55. Grandjean EM, Aubry JM., Lithium:Updated human knowledge using an evidence-based approach. Part II:Clinical pharmacology and therapeutic monitoring. CNS Drugs 2009;23:331–49.
56. Perry PJ, Zeilmann C, Arndt S., Tricyclic antidepressant concentrations in plasma:An estimate of their sensitivity and specificity as a predictor of response. J Clin Psychopharmacol 1994;14:230–40.
57. Spina E, de Leon J., Clinical applications of CYP genotyping in psychiatry. J Neural Transm (Vienna) 2015;122:5–28.
58. Meyer UA., Pharmacogenetics:Five decades of therapeutic lessons from genetic diversity. Nat Rev Genet 2004;5:669–76.
59. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C., Influence of cytochrome P450 polymorphisms on drug therapies:Pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007;116:496–526.
60. Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, Ellingrod VL, et al. Clinical pharmacogenetics implementation consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther 2013;93:402–8.
61. Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S., CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics 2007;17:93–101.
62. Sagud M, Mihaljevic-Peles A, Muck-Seler D, Pivac N, Vuksan-Cusa B, Brataljenovic T, et al. Smoking and schizophrenia. Psychiatr Danub 2009;21:371–5.
63. Miksys S, Tyndale RF., Cytochrome P450-mediated drug metabolism in the brain. J Psychiatry Neurosci 2013;38:152–63.
64. Haslemo T, Eikeseth PH, Tanum L, Molden E, Refsum H., The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. Eur J Clin Pharmacol 2006;62:1049–53.
65. Arranz MJ, de Leon J., Pharmacogenetics and pharmacogenomics of schizophrenia:A review of last decade of research. Mol Psychiatry 2007;12:707–47.
66. Hoge SK, Appelbaum PS., Ethics and neuropsychiatric genetics:A review of major issues. Int J Neuropsychopharmacol 2012;15:1547–57.
67. Bassett AS, Chow EW, AbdelMalik P, Gheorghiu M, Husted J, Weksberg R., The schizophrenia phenotype in 22q11 deletion syndrome. Am J Psychiatry 2003;160:1580–6.
68. Rotman D., Shining light on madness. MIT's Technology Review 2014;117.
69. Krueger RF, Bezdjian S., Enhancing research and treatment of mental disorders with dimensional concepts:Toward DSM-V and ICD-11. World Psychiatry 2009;8:3–6.
70. Aboraya A, France C, Young J, Curci K, Lepage J., The validity of psychiatric diagnosis revisited:The clinician's guide to improve the validity of psychiatric diagnosis. Psychiatry (Edgmont) 2005;2:48–55.
71. Kendell R, Jablensky A., Distinguishing between the validity and utility of psychiatric diagnoses. Am J Psychiatry 2003;160:4–12.
72. Kessler RC, McLaughlin KA, Green JG, Gruber MJ, Sampson NA, Zaslavsky AM, et al. Childhood adversities and adult psychopathology in the WHO World Mental Health Surveys. Br J Psychiatry 2010;197:378–85.
73. Varese F, Smeets F, Drukker M, Lieverse R, Lataster T, Viechtbauer W, et al. Childhood adversities increase the risk of psychosis:A meta-analysis of patient-control, prospective- and cross-sectional cohort studies. Schizophr Bull 2012;38:661–71.
74. Weber K, Rockstroh B, Borgelt J, Awiszus B, Popov T, Hoffmann K, et al. Stress load during childhood affects psychopathology in psychiatric patients. BMC Psychiatry 2008;8:63.
75. Sonnby K, Aslund C, Leppert J, Nilsson KW., Symptoms of ADHD and depression in a large adolescent population:Co-occurring symptoms and associations to experiences of sexual abuse. Nord J Psychiatry 2011;65:315–22.
76. Shih RA, Belmonte PL, Zandi PP., A review of the evidence from family, twin and adoption studies for a genetic contribution to adult psychiatric disorders. Int Rev Psychiatry 2004;16:260–83.
77. van Loo HM, Romeijn JW, de Jonge P, Schoevers RA., Psychiatric comorbidity and causal disease models. Prev Med 2013;57:748–52.
78. Fusar-Poli P, Yung AR, McGorry P, van Os J., Lessons learned from the psychosis high-risk state:Towards a general staging model of prodromal intervention. Psychol Med 2014;44:17–24.
79. Yung AR, McGorry PD., The prodromal phase of first-episode psychosis:Past and current conceptualizations. Schizophr Bull 1996;22:353–70.
80. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E., Mild cognitive impairment:Clinical characterization and outcome. Arch Neurol 1999;56:303–8.
81. Scott J, Leboyer M, Hickie I, Berk M, Kapczinski F, Frank E, et al. Clinical staging in psychiatry:A cross-cutting model of diagnosis with heuristic and practical value. Br J Psychiatry 2013;202:243–5.
82. NIMH. Research Domain Criteria. Available from:http://www.nimh.nih.gov/research-priorities/rdoc/index.shtml [last accessed March 13, 2015].
83. NIMH. Research Domain Criteria Matrix. Available from:http://www.nimh.nih.gov/research-priorities/rdoc/research-domain-criteria-matrix.shtml [last accessed on March 13, 2015].
84. Reardon S., NIH rethinks psychiatry trials. Nature 2014;507:288.
85. NIIMH. National Institute of Mental Health. 2014. Available from:http://www.nimh.nih.gov/about/budget/fy-2016-budget-congressional-justification.shtml [last accessed on March 2, 2015].
86. Glannon W., Research domain criteria:A final paradigm for psychiatry? Front Hum Neurosci 2015;9:488.
87. Carroll BJ., Clinical science and biomarkers:Against RDoC. Acta Psychiatr Scand 2015;132:423–4.
88. Nitta M, Kishimoto T, Muller N, Weiser M, Davidson M, Kane JM, et al. Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia:A meta-analytic investigation of randomized controlled trials. Schizophr Bull 2013;39:1230–41.
89. Muller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Muller B, et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression:Results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 2006;11:680–4.
90. Wu JQ, Kosten TR, Zhang XY., Free radicals, antioxidant defense systems, and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2013;46:200–6.
91. Kelly JR, Kennedy PJ, Cryan JF, Dinan TG, Clarke G, Hyland NP., Breaking down the barriers:The gut microbiome, intestinal permeability and stress-related psychiatric disorders. Front Cell Neurosci 2015;9:392.
92. Yarchoan M, Arnold SE., Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. Diabetes 2014;63:2253–61.
93. Howland RH., Mifepristone as a therapeutic agent in psychiatry. J Psychosoc Nurs Ment Health Serv 2013;51:11–14.
94. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE., Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry 2005;62:593–602.
95. Bekker MH, van Mens-Verhulst J., Anxiety disorders:Sex differences in prevalence, degree, and background, but gender-neutral treatment. Gend Med 2007;4:S178–93.
96. Werling DM, Geschwind DH., Sex differences in autism spectrum disorders. Curr Opin Neurol 2013;26:146–53.
97. McHenry J, Carrier N, Hull E, Kabbaj M., Sex differences in anxiety and depression:Role of testosterone. Front Neuroendocrinol 2014;35:42–57.
98. Crespi BJ., Oxytocin, testosterone, and human social cognition. Biol Rev Camb Philos Soc 2016;91:390–408.
99. Meinhard N, Kessing LV, Vinberg M., The role of estrogen in bipolar disorder, a review. Nord J Psychiatry 2014;68:81–7.
100. Di Florio A, Forty L, Gordon-Smith K, Heron J, Jones L, Craddock N, et al. Perinatal episodes across the mood disorder spectrum. JAMA Psychiatry 2013;70:168–75.
101. Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, et al. Effects of testosterone treatment in older men. N Engl J Med 2016;374:611–24.
102. Miller KK, Perlis RH, Papakostas GI, Mischoulon D, Losifescu DV, Brick DJ, et al. Low-dose transdermal testosterone augmentation therapy improves depression severity in women. CNS Spectr 2009;14:688–94.
103. Rohr UD., The impact of testosterone imbalance on depression and women's health. Maturitas 2002;41:S25–46.
104. Weiner CL, Primeau M, Ehrmann DA., Androgens and mood dysfunction in women:Comparison of women with polycystic ovarian syndrome to healthy controls. Psychosom Med 2004;66:356–62.
105. Feifel D, Shilling PD, MacDonald K., A review of oxytocin's effects on the positive, negative, and cognitive domains of schizophrenia. Biol Psychiatry 2016;79:222–33.
106. Guastella AJ, Hickie IB., Oxytocin treatment, circuitry, and autism:A critical review of the literature placing oxytocin into the autism context. Biol Psychiatry 2016;79:234–42.
107. Preti A, Melis M, Siddi S, Vellante M, Doneddu G, Fadda R., Oxytocin and autism:A systematic review of randomized controlled trials. J Child Adolesc Psychopharmacol 2014;24:54–68.
108. Talaei A, Pourgholami M, Khatibi-Moghadam H, Faridhosseini F, Farhoudi F, Askari-Noghani A, et al. Tamoxifen:A protein kinase C inhibitor to treat mania:A systematic review and meta-analysis of randomized, placebo-controlled trials. J Clin Psychopharmacol 2016;36:272–5.